Iaso Therapeutics

About Iaso Therapeutics

Iaso Therapeutics is dedicated to developing next-generation vaccines to enhance human health and treat diseases. Their mission is to redefine infectious disease prevention by building a synthetic antigen vaccine platform to combat antimicrobial resistance, delivering broad-spectrum vaccines with rapid protection, room-temperature stability, and global scalability.

Products & Services

Synthetic Antigen Vaccine Platform:Integrates precision synthetic antigens with a powerful mQβ VLP carrier to elicit robust, durable, and antigen-focused immunity. Features rapid design-to-clinic timelines, synthetic control for broad coverage, immune optimization, high immunogenicity, and validation by third-party clinical trials.

Mutant Qβ Platform (mQβ VLP):A disruptive virus-like particle that shows superiority in generating antibodies compared to traditional conjugate carrier proteins. Now sold by Fina Biosolutions.

Specialties

Next-generation vaccines Synthetic antigen vaccine platform Virus-like particle technology (mQβ VLP) Infectious disease prevention Antimicrobial resistance solutions

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series Seed Preferred T: - FT: Series Seed Preferred	A: 1250000 MR: - FA: $1.25M FAN: 1250000	D: 2023-01-25 FD: 2023-01-25	4 investors

Series Seed Preferred Latest

2023-01-25

$1.2M

4 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

J

Jack Luderer

Entrepreneur in Residence

F

Florian Schödel

VP, Vaccines Clinical Research

D

Dean Shinabarger

X

Xinzhen Yang

MD, PhD

L

Leo Parks

Professor

A

Ananda Chakrabarty

Doctor

View 12 more team members with Pro

Unlock Full Team Directory

Recent News